Amyloid-directed therapy landscape movement
Review Window: Q4 2025 – Q2 2026
Assessment
Three trial readouts, one regulatory action, and one payer policy shift since the last review window.
Re-review trigger
Re-review candidate — movement spans trial, regulatory, and coverage sourcesDocumented Movements (6)
- ARIAS Phase III trial high significance
Primary endpoint met; safety profile consistent with earlier studies
- FDA high significance
ARIA monitoring protocol established in label
- CMS coverage database medium significance
All major payers reflected in coverage records; no restriction change
- Expanded-access cohort medium significance
Safety data published (n=412) showing real-world protocol-adjacent outcomes
- Multi-site RCT medium significance
ARIA incidence rate reported at 14.2% in treated population
- Payer policy document low significance
One published policy narrowed biomarker confirmation requirements
Decision Implications
The public record through May 2026 shows no controlled change that would authorize broad routine coverage outside tightly defined criteria. The restriction position remains supportable, but multiple sources now carry weight that did not exist at the last review. A committee reading this note can see that the evidence base has moved without the conclusion tipping — exactly the situation a full baseline would assess against a specific decision window.